The open index of psychedelic research

Psychedelics as prophylactic neuroprotectants.

Maiarú M

Private cannabis prescribing in England after SI 2018/1055 (NHSBSA FOI-03941 aggregates), with NHS primary-care comparator series and UK 2018 / US 2026 regulatory event tables

Tamba, Hiroki

Focused Ultrasound for Prolonged Grief Disorder: A Novel Approach to Targeting Reward Circuitry Underlying Persistent Yearning and Related Clinical Features.

Manevich A, Prigerson HG

Age and Cannabis Co-Use Are Associated with Differences in Experience and Perceived Benefits of Psilocybin: A Retrospective Study.

Hooper J, Williams S, Mueller R +1

Drug purchasing offline and online (social media and messaging apps) in Poland – online survey data (2023–2025)

Siuda, Piotr, Stasiak, Adam

Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized Clinical Trial.

Orsini DK, Di Luch S, Tomlinson G +18

Heterogeneous structural brain signatures of methamphetamine and ketamine use disorders revealed by normative modeling.

Sun Y, Fang Y, Peng P +3

Esketamine Use and Attempted Suicide or Intentional Self-Harm Among Individuals with Treatment-Resistant Depression: A Retrospective Cohort Study.

Wang Y, Storaci AS, Alexander GC +1

A response to the letter to editor: Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy.

Khan FA, Pandupuspitasari NS, Tencomnao T +1

<i>In Vitro</i> Ketamine Attenuates Immune Sensitization in Major Depressive Disorder in a Concentration-Dependent Manner

Zhang Y, Zhuang X, Niu M +7

Neuroinflammation in postoperative cognitive dysfunction: the multi-target potential of esketamine in modulating microglial responses and synaptic integrity.

Li HT, Lin GY, Xing WT +2

Comment on "Esketamine versus dexmedetomidine fora oxygenation and postoperative quality of recovery in thoracoscopic surgery: a randomized, double‑blind, non-inferiority controlled trial" by Feng et al.

Liu J, Sheng Z

Justice Involvement and Hallucinogen Use Among US Adults: Exploring Health Problems, Other Substance Use, and Demographic Correlates.

Karaaslan FG, Philippon C, Ford JA

Quality of Recovery-15 After Opioid-free Versus Opioid-based General Anesthesia in Major Urological Surgery

Pharmacometabolomics of Psychotropic Drugs: Treatment Response, Adverse Effects, and Precision Psychiatry—A Narrative Review

SV SK

Spatiotemporal Dynamics of the Flow Experience: An EEG Microstate Analysis.

Khoshnoud S, Igarzábal FA, Wittmann M

Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT.

Simonsson O, Bradley M, Black JC +3

Psilocybin, From Ancestral Use to Therapeutic Potential: A Multidimensional Review of Its Pharmacological Basis and Current Perspectives.

Vásquez-Bonilla JN

Psychedelics in psychiatry: comparative effectiveness, implementation, commercialization and safety lessons learned from intranasal esketamine.

McIntyre RS

Contribution of the Serotonin 5-HT&lt;sub&gt;2A&lt;/sub&gt; Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress.

Ibi D, Takaba R, Yoshida K +8

Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD.

Agin-Liebes G, Shnayder S, Fram G +6

Ketamine Dose and Duration Effects in Internalizing Disorders.

McNaughton N, Beaglehole B, Glue P

Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing

Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)